The Indian Pharma

Bortezomib Injection

 

  • API: Bortezomib
  • Packaging & Strength: Injection: 2 mg and 3.5 mg
Get Price

Description

Uses of Medicine:

Bortezomib injection is a proteasome inhibitor. It is supplied generically as well as brand-name medicine. Patients, Healthcare Professionals (HCPs), or Hospitals can buy Bortezomib 2 MG/3.5 MG injections online from India through THE INDIAN PHARMA (a trusted Bortezomib Supplier, Exporter, and Contract Manufacturer in India) for the management and treatment of:
  • Multiple Myeloma (MM): Bortezomib 2 mg/3.4 mg injection is used for the treatment of adult patients with multiple myeloma (MM). 
  • Mantle Cell Lymphoma (MCL): Bortezomib 2 mg/3.4 mg injection is for the treatment of adult patients with mantle cell lymphoma. 
  Bortezomib 2 mg/3.5 mg is the specific medicine used for the treatment of multiple myeloma (MM) and mantle cell lymphoma (MCL). Multiple myeloma is the neoplastic transformation of plasma cells which is prevalent in the bone marrow. Mantle cell lymphoma is a subclass of non-Hodgkin’s lymphomas that involves lymph nodes which is not very frequent. This therapeutic drug is used in combination with other chemotherapy agents like pegylated liposomal doxorubicin, rituximab, cyclophosphamide, doxorubicin, dexamethasone, prednisolone, or thalidomide for patients who are not yet treated and are not candidates for blood stem cell transplantation. Let your physician know if you have an allergy to Bortezomib 2 mg/3.5 mg Injection. This medication should not be taken when suffering from severe lung and heart diseases. Let your physician know if you have any of these conditions: cardiac abnormalities, serious pulmonary issues, posterior reversible encephalopathy syndrome, alcoholism, severe neuropathy disorder, gastrointestinal problems, thrombocytopenia, neutropenia, tumor lysis syndrome, or metabolic dysfunctions associated with liver damage. It is also important to mention that you have diabetes, as this injection can alter your blood sugar levels.  

Dosage & Side Effects: 

The recommended dose of Bortezomib is given through an injection into the vein (IV). The injection is very quick (3 to 5 seconds). The way it is given depends on the condition being treated.
  • For New Patients with Multiple Myeloma: The first 4 treatment cycles last 42 days each. Bortezomib is given on days 1, 4, 8, 11, 22, 25, 29, and 32 of the cycle. The doses must be at least 72 hours apart. After the first 4 cycles, the dose schedule changes to days 1, 8, 22, and 29 of a 42-day cycle. It is usually given with other medicines.
  • For Patients Who Had Multiple Myeloma Before (Relapsed Myeloma): Bortezomib is given on days 1, 4, 8, and 11 of a 21-day cycle. If the patient has had Bortezomib before, treatment may continue for up to 8 cycles. After 8 cycles, the dose schedule changes to days 1, 8, 15, and 22 of a 35-day cycle.The doses must be at least 72 hours apart. It can be given alone or with dexamethasone.
  • For Mantle Cell Lymphoma: Bortezomib is given on days 1, 4, 8, and 11 of a 21-day cycle. The doses must be at least 72 hours apart. Do not inject at the same spot in the same cycle to avoid irritation.
  The most common side effects of Bortezomib 2 mg/3.5 mg Injection are nausea, leukopenia, diarrhea, rash, vomiting, fatigue, thrombocytopenia, pyrexia, neutropenia, peripheral neuropathy, neuralgia, anemia, constipation, lymphopenia, and anorexia.
× How can I Help you?